Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy

Inclusion Criteria: * Male or female subjects \>/= 18 years of age * Life expectancy of at least 3 months * Histological or cytological documentation of adenocarcinoma of the colon or rectum * Subjects with metastatic colorectal cancer (Stage IV) * Progression during or within 3 months following the last administration of approved standard therapies which must include fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab and cetuximab/panitumumab if KRAS WT (WT: wild-type i.e. no KRAS mutation) * Eastern Cooperative Oncology Group (ECOG) Performance Status of \</= 1 * Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements * Women of childbearing potential and men must agree to use adequate contraception since signing of the inform consent (IC) form until at least 3 months after the last study drug administration Exclusion Criteria: * Prior treatment with regorafenib * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study drug * Pregnant or breast-feeding subjects * Congestive heart failure \>/= New York Heart Association (NYHA) class 2 * Myocardial infarction less than 6 months before start of study drug * Ongoing infection \> Grade 2 Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0 * Renal failure requiring hemo-or peritoneal dialysis